| Literature DB >> 35063380 |
Josef Finsterer1, Claudia Stollberger2.
Abstract
Entities:
Keywords: COVID-19; SARS-CoV-2; Side effect; Takotsubo; Vaccination
Mesh:
Substances:
Year: 2022 PMID: 35063380 PMCID: PMC8767954 DOI: 10.1016/j.hlc.2021.12.010
Source DB: PubMed Journal: Heart Lung Circ ISSN: 1443-9506 Impact factor: 2.838
SARS-CoV-2 vaccination triggered TTS reported as per the end of November 2021.
| Age | Sex | Brand | LAOT | TTS Type | Treatment | Outcome | Reference |
|---|---|---|---|---|---|---|---|
| 63 | F | 1. Moderna | 1 d | Classical | None | nr | [ |
| 72 | M | 1. AZV | 4 d | Classical | Dual APT | CR | [ |
| 65 | F | 1. Moderna | 2 d | Classical | Aspirin, atorvastatin, lisinopril, metoprolol | IR | [ |
| 80 | F | 1. Pfizer | 4 d | Classical | None | IR | [ |
| 73 | F | 1. Moderna | nr | Classical | Metoprolol, losartan | IR | [ |
Abbreviations: APT, antiplatelet therapy; AZV, Astra Zeneca vaccine; CR, complete recovery; IR, incomplete recovery at last follow-up; LAOT, latency between vaccination and onset of TTS; nr, not reported.